1. Home
  2. /
  3. Venture Capital
  4. /
  5. MIMETAS participates in €325...

Venture Capital

MIMETAS participates in €325 M Oncode-PACT initiative to accelerate and improve oncology drug development

14 April 2022
Oncode Institute will lead the Oncode-PACT consortium and its operations. With this investment, the consortium will develop cancer drug candidates faster and bring them to patients sooner. As a partner in Oncode-PACT, MIMETAS will develop the next generation of patient-specific cancer organoid models that include immune cells, blood vessels, and other essential cell types to drive novel cancer drug discovery and development. Using these models, MIMETAS will screen compounds and targets using fully integrated, automatic phenotypic screening lines with AI data interpretation, bringing early validation and de-risking to the cancer drug development pipeline.

Related News

arrow-up-right
Deepull-logo
arrow-up-right